What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Internal medicine, Targeted therapy, Immunology, Radiation therapy and Oncolytic virus.
His work deals with themes such as Surgery and Oncology, which intersect with Internal medicine.
His study of Head and neck cancer is a part of Surgery.
His Targeted therapy study is concerned with Cancer in general.
His studies in Immunology integrate themes in fields like Cancer research and Genetic enhancement.
His study in the field of Chemoradiotherapy also crosses realms of In patient.
His most cited work include:
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (1979 citations)
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma (1183 citations)
- Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. (1039 citations)
What are the main themes of his work throughout his whole career to date?
Kevin J. Harrington focuses on Internal medicine, Oncology, Radiation therapy, Targeted therapy and Head and neck cancer.
Many of his studies on Internal medicine apply to Gastroenterology as well.
His work is dedicated to discovering how Oncology, Head and neck are connected with Basal cell and other disciplines.
His Radiation therapy research incorporates elements of Nuclear medicine and Dysphagia.
His Targeted therapy research includes themes of Cancer research, Genetic enhancement, Oncolytic virus and Pathology.
His research in Head and neck cancer intersects with topics in Quality of life, Randomized controlled trial and Swallowing.
He most often published in these fields:
- Internal medicine (39.89%)
- Oncology (31.70%)
- Radiation therapy (36.82%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (39.89%)
- Oncology (31.70%)
- Cancer research (22.84%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Cancer research, Radiation therapy and Oncolytic virus.
His is involved in several facets of Internal medicine study, as is seen by his studies on Chemotherapy, Head and neck squamous-cell carcinoma, Cetuximab, Head and neck cancer and Clinical trial.
His study in Oncology is interdisciplinary in nature, drawing from both Pembrolizumab, Cancer, Targeted therapy, Nivolumab and Immunotherapy.
His Cancer research research includes elements of Cancer cell, Immunogenic cell death, Immune system and Immune checkpoint.
His Radiation therapy study which covers Magnetic resonance imaging that intersects with Stage.
The study incorporates disciplines such as Cytotoxic T cell, Melanoma, Talimogene laherparepvec and Cancer immunotherapy in addition to Oncolytic virus.
Between 2017 and 2021, his most popular works were:
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study (409 citations)
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study (409 citations)
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study (380 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary areas of study are Internal medicine, Oncology, Cancer research, Radiation therapy and Immunotherapy.
His Internal medicine study focuses mostly on Nivolumab, Docetaxel, Hazard ratio, Phases of clinical research and Head and neck cancer.
Kevin J. Harrington combines subjects such as Pembrolizumab, Cetuximab, Chemotherapy, Head and neck squamous-cell carcinoma and Clinical endpoint with his study of Oncology.
His Cancer research research is multidisciplinary, incorporating perspectives in Cancer cell, Interferon, Immune system and In vivo.
His Radiation therapy research is within the category of Radiology.
His work carried out in the field of Immunotherapy brings together such families of science as Glioma, Oncolytic virus and Head and neck.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
